title: Downregulation of the adenosine a2b receptor by RNA interference inhibits hepatocellular carcinoma cell growth.
abstract: To investigate the biological effect of adenosine A2b receptor (A2bR) on the human hepatocellular carcinoma cell line HepG2, three A2bR siRNA constructs were transiently transfected into HepG2 cells. The results showed that A2bR siRNA reduced the levels of A2bR mRNA and protein. In order to further detect the function of A2bR, we established a stable hepatocellular carcinoma cell line (HepG2) expressing siRNA targeting the adenosine A2b receptor. Targeted RNAi significantly inhibited tumor cell growth in vitro, and flow cytometry (FCM) showed that significantly more cells expressing A2bR siRNA were in the G0/G1 phase compared to the untransfected group ((89.56% ± 3.15%) versus (56.19% ± 1.58%), P < 0.01). These results indicated that silencing the expression of adenosine A2b receptor in HepG2 cells can suppress cell growth effectively by blocking the cell cycle. Downregulation of adenosine A2b receptor gene expression with RNA interference could be a new approach to hepatocellular carcinoma therapy.
authors.affiliation: Department of Hepatobiliary Surgery, Lanzhou General Hospital, Lanzhou Military Area Command of Chinese People's Liberation Army, 98 XiaoXiHu Road, Lanzhou 730050, China.
authors.forename: Hong-Jun
authors.initials: HJ
authors.lastname: Xiang
authors.forename: Fu-Lu
authors.initials: FL
authors.lastname: Chai
authors.forename: De-Sheng
authors.initials: DS
authors.lastname: Wang
authors.forename: Ke-Feng
authors.initials: KF
authors.lastname: Dou
references.citation: Cancer Res. 1989 Dec 1;49(23):6449-65
references.pmid: 2684393
references.citation: Nature. 2002 Jul 25;418(6896):435-8
references.pmid: 12087358
references.citation: Hepatogastroenterology. 2000 Nov-Dec;47(36):1663-8
references.pmid: 11149028
references.citation: Hepatology. 1997 Jun;25(6):1376-81
references.pmid: 9185756
references.citation: Med Oncol. 2001;18(4):243-59
references.pmid: 11918451
references.citation: Drug Discov Today. 2002 Oct 15;7(20):1040-6
references.pmid: 12546893
references.citation: Nature. 2001 May 24;411(6836):494-8
references.pmid: 11373684
references.citation: Biochem Biophys Res Commun. 1993 Oct 29;196(2):1010-6
references.pmid: 8240318
references.citation: Mol Pharmacol. 1986 Apr;29(4):331-46
references.pmid: 3010074
references.citation: Nature. 1998 Feb 19;391(6669):806-11
references.pmid: 9486653
references.citation: Cancer Res. 1997 Jul 1;57(13):2602-5
references.pmid: 9205063
references.citation: Nature. 2003 Jan 16;421(6920):220-1
references.pmid: 12529623
references.citation: J Clin Invest. 1995 Oct;96(4):1979-86
references.pmid: 7560091
references.citation: Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17216-21
references.pmid: 15563600
references.citation: Science. 2002 Apr 19;296(5567):550-3
references.pmid: 11910072
references.citation: Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):380-4
references.pmid: 15734961
references.citation: Int J Cancer. 2001 Oct 15;94(2):153-6
references.pmid: 11668491
references.citation: Pharmacol Rev. 2001 Dec;53(4):527-52
references.pmid: 11734617
references.citation: Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2014-8
references.pmid: 12566571
references.citation: Cell Mol Neurobiol. 1983 Mar;3(1):69-80
references.pmid: 6309393
references.citation: J Virol. 2003 Jul;77(13):7159-65
references.pmid: 12805414
references.citation: Nature. 2003 Jan 16;421(6920):268-72
references.pmid: 12529643
references.citation: Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13437-42
references.pmid: 11687652
references.citation: Nat Biotechnol. 2002 May;20(5):505-8
references.pmid: 11981566
references.citation: Hepatol Res. 2006 Sep;36(1):56-60
references.pmid: 16844405
references.citation: Semin Cancer Biol. 2004 Aug;14(4):223-30
references.pmid: 15219615
references.citation: Int J Oncol. 1999 Jan;14(1):127-31
references.pmid: 9863018
references.citation: Hypertension. 1996 Mar;27(3 Pt 2):786-93
references.pmid: 8613241
references.citation: Annu Rev Pharmacol Toxicol. 2001;41:775-87
references.pmid: 11264476
references.citation: Nature. 2002 Jul 11;418(6894):244-51
references.pmid: 12110901
references.citation: Pharmacol Ther. 2000 Aug-Sep;87(2-3):161-73
references.pmid: 11007998
references.citation: Pulm Pharmacol. 1991;4(2):114-9
references.pmid: 1804499
references.citation: Mol Ther. 2002 Aug;6(2):243-51
references.pmid: 12161191
references.citation: Br J Pharmacol. 1996 Jan;117(1):170-4
references.pmid: 8825359
references.citation: Prog Neurobiol. 1996 Feb;48(3):167-89
references.pmid: 8735876